Overview

Harvard Atherosclerosis Reversibility Project (HARP)

Status:
Completed
Trial end date:
1992-11-01
Target enrollment:
Participant gender:
Summary
To determine by sequential coronary arteriography whether a lipid-lowering diet with and without lipid-lowering drugs could reverse coronary artery disease in normocholesterolemic patients. Also, to test whether fish oil supplements could improve human coronary atherosclerosis. Finally, to determine the effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. At least three clinical trials were conducted.
Phase:
Phase 2
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Cholestyramine Resin
Gemfibrozil
Niacin
Pravastatin